A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19
Study Details
Study Description
Brief Summary
This study is to evaluate the efficacy of post-exposure prevention and safety of HH-120 nasal spray in participants who are caregivers of hospitalized patients infected with SARS-CoV-2. HH-120 nasal spray are administrated 8-10 times to the participants per day until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: HH-120 Nasal Spray
|
Drug: HH-120 Nasal Spray
HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day, until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.
|
Outcome Measures
Primary Outcome Measures
- The proportion of subjects infected with SARS-CoV-2 [As of the discharge of the SARS-CoV-2 infected patients, an average 1 week]
Secondary Outcome Measures
- The incidence and severity of adverse events and the serious adverse events [As of the 7th day after the last study drug administration]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male and female subjects aged 18 or above;
-
Caregivers of hospitalized children who are infected with SARS-CoV-2;
-
Negative qRT-PCR nucleic acid test result during the screening;
-
Willing and able to give written informed consent.
Exclusion Criteria:
-
Those who have child-bearing plan or are unable to voluntarily take effective contraceptive measures, or plan to donate sperm/ovum during the study or within 3 months after the end of the study;
-
Female subjects who are positive for human chorionic gonadotropin (β-Human Chorionic Gonadotropin, β-HCG) or are breastfeeding;
-
Have used antiviral drugs with a therapeutic effect on COVID-19 within 3 months before screening, including various monoclonal antibodies (tixagevimab and cilgavimab, tocilizumab, ambavirumab and romisvir, Bamlanivimab, Etesevimab, Bebtelovimab, Casirivimab and imdevimab, Sotrovimab), convalescent plasma, hydroxychloroquine, Paxlovid (Nimatevir/ritonavir), Azvudine, Baricitinib, molnupiravir, remdesivir, interference drug, ribavirin, arbidol and lopinavir, etc.; (except those with the wash-out time longer than 5 half-lives);
-
Those who have participated in clinical trials of SARS-CoV-2 neutralizing antibodies or participated in clinical trials of other drugs within 4 weeks before screening;
-
Those who have a history of severe allergies or are sensitive to inhaled allergens; or are known to be sensitive to the ingredients of the study drug, other monoclonal antibody drugs, and therapeutic protein preparations (fresh or frozen plasma, human serum albumin, cytokines, interleukin, etc.) Factors, etc.) have allergies or hypersensitivity reactions;
-
Those who have received the COVID-19 vaccine within 2 weeks before the study drug administration or plan to receive the COVID-19 vaccine during the study;
-
Those who cannot tolerate with nasal spray treatment;
-
Any other circumstances that the researchers deemed not suitable for participating in the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beijing Ditan Hospital,Capital Medical University | Beijing | Beijing | China | 100015 |
Sponsors and Collaborators
- Beijing Ditan Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HH120-IIT-NS01